Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients

Basic and Clinical Pharmacology and Toxicology

Volumn 98, Issue 2, 2006, Pages 197-200

  Gunes, Arzu ^a   Coskun, Ugur ^a   Boruban, Cem ^b   Gunel, Nazan ^a   Babaoglu, Melih O ^c   Sencan, Orhan ^b   Bozkurt, Atila ^c   Rane, Anders ^d   Hassan, Moustapha ^d   Zengil, Hakan ^a   Yasar, Umit ^c  

^a GAZI UNIVERSITY   (Turkey)

^b ANKARA NUMUNE HOSPITAL   (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; CYTOCHROME P450 2C9; FLUOROURACIL; FOLINIC ACID; LOSARTAN; LOSARTAN POTASSIUM;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENOTYPE; HUMAN; MALE; PHENOTYPE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ARYL HYDROCARBON HYDROXYLASES; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; IMIDAZOLES; LOSARTAN; MALE; MIDDLE AGED; OXIDATION-REDUCTION; TETRAZOLES;

EID: 33645061280     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.pto_304.x     Document Type: Article

References (21)

1. Afsar A. C. Lee D. S. Riddick Modulation of the expression on constitutive rat hepatic cytochrome P450 isozymes by 5-fluorouracil Can. J. Physiol Pharmacol. 1996 74 150 156
2. Babaoglu M. O. U. Yasar M. Sandberg E. Eliasson M. L. Dahl S. O. Kayaalp A. Bozkurt CYP2C9 genetic variants and losartan oxidation in a Turkish population Eur. J. Clin. Pharmacol. 2004 60 337 342
3. Brickell K. D. Porter P. Thompson Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports Brit. J. Cancer 2003 89 615 616
4. Brown M. C. Multisite mucous membrane bleeding due to a possible interaction between warfarin and 5-fluorouracil Pharmacotherapy 1997 17 631 633
5. Brown M. C. An adverse interaction between warfarin and 5-fluorouracil: A case report and review of the literature Chemotherapy 1999 45 392 395
6. Camidge R. B. Reigner J. Cassidy S. Grange M. Abt E. Weidekamm D. Jodrell Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer J. Clin. Oncol. 2005 23 4719 4725
7. Gilbar P. J. T. R. Brodribb Phenytoin and fluorouracil interaction Ann. Pharmacotherap. 2001 35 1367 1370
8. Gonzalez F. J. P. Fernandez-Salguero Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency Trends Pharmacol. Sci. 1995 16 325 327
9. Kolesar J. M. C. L. Johnson B. L. Freeberg J. D. Berlin J. H. Schiller Warfarin-5-FU interaction - a consecutive case series Pharmacotherapy 1999 19 1445 1449
10. Konishi H. K. Morita T. Minouchi M. Nakajima M. Matsuda A. Yamaji Probable metabolic interaction of doxifluridine with phenytoin Ann. Pharmacother. 2002 36 831 834
11. Lee C. R. J. A. Goldstein J. A. Pieper Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data Pharmacogenetics 2002 12 251 263
12. McLeod H. L. J. Sludden S. C. Hardy R. E. Lock G. M. Hawksworth J. Cassidy Autoregulation of 5-fluorouracil metabolism Eur. J. Cancer 1998 34 1623 1627
13. Park J. Y. K. A. Kim Inhibitory effect of 5-fluorouracil on human cytochrome P(450) isoforms in human liver microsomes Eur. J. Clin. Pharmacol. 2003 59 407 409
14. Rich T. A. R. C. Shepard S. T. Mosley Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy J. Clin. Oncol. 2004 22 2214 2232
15. Rosemergy I. M. Findlay Phenytoin toxicity as a result of 5-fluorouracil administration N. Z. Med. J. 2002 115 U124
16. Schilsky R. L. Biochemical and clinical pharmacology of 5-fluorouracil Oncology (Williston. Park) 1998 12 13 18
17. Stupans I. D. A. Richards M. T. McClure Effects of 5-fluorouracil treatment on rat liver microsomal enzymes Xenobiotica 1995 25 1 8
18. Yasar U. E. Eliasson M. L. Dahl I. Johansson M. Ingelman-Sundberg F. Sjöqvist Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population Biochem. Biophys. Res. Commun. 1999 254 628 631
19. Yasar U. C. Forslund-Bergengren G. Tybring P. Dorado A. Llerena F. Sjöqvist E. Eliasson M. L. Dahl Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype Clin. Pharmacol. Therap. 2002 71 89 98
20. Yasar U. G. Tybring M. Hidestrand M. Oscarson M. Ingelman-Sundberg M. L. Dahl E. Eliasson Role of CYP2C9 polymorphism in losartan oxidation Drug Metab Dispos. 2001 29 1051 1056
21. Yoshisue K. S. Nagayama T. Shindo Y. Kawaguchi Effects of 5-fluorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats J. Pharmacol. Exp. Therap. 2001 297 1166 1175